Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Relmada Therapeutics Inc.

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Relmada Therapeutics yesterday and set a price target of $19.00. Ear covers the Healthc...

Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)

Relmada Therapeutics Inc (($RLMD)) has held its Q4 earnings call. Read on for the main highlights of the call. Relmada Therapeutics’ latest earning...

Relmada Therapeutics Charts Aggressive Path After Earnings Call

The latest announcement is out from Relmada Therapeutics ( ($RLMD) ). Relmada Therapeutics reported audited fourth-quarter and full-year 2025 resul...

Relmada Highlights NDV-01 Data, Funding in 2025 Results

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. The Phase 3 study titled “A Phase 3 Study of NDV-01 as an Int...

Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. The BOOST study, officially titled “A Phase 3, Randomized Stu...

Relmada’s Withdrawn BOOST Trial Resets Expectations for NDV-01 and RLMD

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gain Therapeutics (GANX – Research Report) and Relma...

Analysts’ Top Healthcare Picks: Gain Therapeutics (GANX), Relmada Therapeutics (RLMD)

Investors seeking the top stock market stories for Monday will want to check out the daily wrap-up.


Current Quarter	$-0.18	Next Quarter	$-0.19
Current Year	$-0.72	Next Year	$-1.18
QoQ Growth	-5.6%	YoY Growth	-63.9%
3Y EPS CAGR	+28.2%	Target Price	$12.80
Consensus	Buy	Upside	+83.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RLMD	$6.97	+3.19%	458.55K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RLMD	$6.97	+3.2%	458.55K
3
4
5
6

RLMD

RLMD

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Relmada Therapeutics Inc. Data in Excel

Get Relmada Therapeutics Inc. Data in Excel